P-206: SELECT Trial in Progress: an open-label, phase 2 study of Carfilzomib, Pomalidomide, and Dexamethasone in patients with first or second relapse of Multiple Myeloma

Article2024

An open-label phase 2 study treating patients with first or second relapse of multiple myeloma with carfilzomib, pomalidomide, and dexamethasone (KPd): SELECT study

Aurore Perrot, Sosana Delimpasi, Emmanouil Spanoudakis, Ulf Christian Frølund, Angelo Belotti, Albert Oriol, Philippe Moreau, Ian McFadden, Qing Xia, Mukta Arora, Meletios A Dimopoulos

Article2021

Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial

Meletios A Dimopoulos, Evangelos Terpos, Mario Boccadoro, Sosana Delimpasi, Meral Beksaç, Eirini Katodritou, Philippe Moreau, Luca Baldini, Argiris Symeonidis, Jelena Bila, Albert Oriol, María‐Victoria Mateos, Hermann Einsele, Ioannis Orfanidis, Tahamtan Ahmadi, Jon Ukropec, Tobias Kampfenkel, Jordan M. Schecter, Yanping Qiu, Himal Amin, Jessica Vermeulen, Robin Carson, Pieter Sonneveld, Adrián Alegre Amor, Luca Baldini, Meral Beksaç, Angelo Belotti, Lotfi Benboubker, Britta Besemer, Sevgi Kalayoğlu Beşışık, Jelena Bila, Mario Boccadoro, Michèle Cavo,

Article2015

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

Meletios A Dimopoulos, Philippe Moreau, Antonio Palumbo, Douglas Joshua, Luděk Pour, Roman Hájek, Thierry Façon, Heinz Ludwig, Albert Oriol, Hartmut Goldschmidt, Laura Rosiñol, Jan Štraub, Aleksandr Suvorov, Carla Araujo, Elena Rimashevskaya, Tomáš Pika, Gianluca Gaïdano, Katja Weisel, Vesselina Goranova‐Marinova, Anthony P. Schwarer, Leonard Minuk,

Article2019

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Paul G. Richardson, Albert Oriol, Meral Beksaç, Anna Marina Liberati, Mónica Galli, Fredrik Schjesvold, Jindriska Lindsay, Katja Weisel, Darrell White, Thierry Façon, Jesús F. San Miguel, Kazutaka Sunami, Peter O’Gorman, Pieter Sonneveld, Paweł Robak, С. В. Семочкин, Steve Schey, Xin Yu, Thomas Doerr, Amine Bensmaine, Tsvetan Biyukov, Teresa Peluso,

Article2021

Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial

Philippe Moreau, Meletios A Dimopoulos, Joseph Mıkhael, Kwee Yong, Marcelo Capra, Thierry Façon, Roman Hájek, Ivan Špıčka, Ross Baker, Kihyun Kım, Gracia Martínez, Chang‐Ki Min, Luděk Pour, Xavier Leleu, Albert Oriol, Youngil Koh, Kenshi Suzuki, Marie‐Laure Risse, Gaëlle Asset, Sandrine Macé, Thomas G. Martin, Philippe Moreau, Meletios A Dimopoulos,

Discussion(0)

Related publications